Latest News

The therapy builds on long-standing research led by Prof. Rami Aqeilan of the Hebrew University of Jerusalem, who helped uncover the critical role of the WWOX gene in brain development.

The researchers designed the device to work seamlessly with existing medical imaging technologies, including ultrasound and CT scans.

The agreement includes an upfront payment of US$1.25 billion, with additional milestone-based payments of up to US$750 million tied to future sales performance.

The company has invested nearly US$5 billion in the United States over the past 15 years, expanding its manufacturing, research, development, and distribution infrastructure.

The deal integrates Firefly Bio’s experimental Firelink degrader-antibody conjugate platform into J&J’s oncology research and development portfolio, marking a significant step in its long-term strategy to enhance targeted drug delivery systems.

The hospital introduced the programme as part of broader efforts to reduce the burden of airborne diseases through stronger community engagement and evidence-based interventions.

The move comes as Teva advances plans to divest its API unit, Teva Active Pharmaceutical Ingredients (TAPI), a process first announced in January 2024.

The facility will occupy approximately 3,000 square metres and will comprise a ground floor, five upper levels, and a rooftop, reaching a height of 27.75 metres.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

Under the new agreement, EDE and Novo Nordisk will work together to enhance pharmaceutical supply chain security by increasing in-country value creation and expanding strategic partnerships that help maintain a steady supply of medicines.